Increased Survival in Pancreatic Cancer With Nab Paclitaxel Plus Gemcitabine

This book aims to provide an update in the current state of play in pancreatic cancer diagnosis and to evaluate the benefits and limitations of the available diagnostic technology and therapy.

This book provides an overview of the current challenges and states of pancreatic cancer and pancreatic neuroendocrine tumors, including information on diagnostic tools, treatment strategies, and mechanisms of pancreatic cancer therapy resistance.

Worldwide, there are an estimated 232, 000 new cases of pancreatic cancer annually. In the United States, it is the fourth leading cause of cancer death, and approximately 30,000 people die of pancreatic cancer each year. The disease is difficult to diagnose in its early stages, and most patients have incurable disease by the time they present with symptoms. The overall 5-year survival rate for this disease is less than 5%.

This book provides a comprehensive, state-of-the art review of current and new therapies in treating pancreatic cancer.

This book provides state of the art knowledge on a broad range of clinical issues in pancreatic cancer, covering topics from screening and pathophysiology to surgical treatments.

This book provides state of the art knowledge on a broad range of clinical issues in pancreatic cancer, covering topics from screening and pathophysiology to surgical treatments. In particular, the focus is on current controversies and on evidence-based surgical techniques. Further aspects considered include the management of precancerous lesions, diagnostic methods,